The Mesoblast Limited (ASX: MSB) share price has been amongst the best performers on the All Ordinaries index on Tuesday.
In morning trade the allogeneic cellular medicines developer’s shares surged a sizeable 17% higher to $1.70 following a positive update.
What did Mesoblast announce?
This morning Mesoblast announced that it has entered into a strategic partnership with global pain management leader Grünenthal to develop and commercialise MPC-06-ID.
According to the release, MPC-06-ID is a Phase III allogeneic cell therapy candidate for the treatment of chronic low back pain due to degenerative disc disease in patients that have exhausted conservative treatment options.
Under the partnership, Grünenthal will have exclusive commercialisation rights to MPC-06-ID for Europe and Latin America.
In exchange for this, Mesoblast will receive up to US$150 million in upfront and milestone payments prior to product launch, as well as further commercialisation milestone payments.
These payments include commitments up to US$45 million within the first year comprising US$15 million on signing, US$20 million on receiving regulatory approval to begin a confirmatory Phase III trial in Europe, and US$10 million on certain clinical and manufacturing outcomes.
But it doesn’t stop there. The release advises that cumulative milestone payments could exceed US$1 billion depending on the final outcome of Phase III studies and patient adoption. Mesoblast will also receive tiered double-digit royalties on product sales.
Mesoblast is currently completing a Phase III trial for MPC-06-ID in the United States, with the results due in 2020.
In a previous U.S. Phase II trial, the company demonstrated that a single intra-discal injection of MPC-06-ID using a unit dose of 6 million allogeneic mesenchymal precursor cells resulted in meaningful and durable improvements for patients in pain intensity and functionality for at least three years.
Mesoblast’s chief executive, Dr Silviu Itescu, said: “We are very pleased to enter into this strategic partnership with Grünenthal, a world leader in innovative approaches to pain management. Together with Grünenthal we plan to bring an important new class of therapy for pain management to the many patients suffering with degenerative disc disease. This partnership is in line with our corporate strategy to team up with best in category commercial leaders to maximise market access for our innovative cellular medicines for the treatment of patients suffering from debilitating or life-threatening inflammatory conditions.”
This looks to be a very good deal for Mesoblast and I can’t say I’m surprised to see its shares charge higher today along with fellow high-flyers iSignthis Ltd (ASX: ISX) and Paradigm Biopharmaceuticals Ltd (ASX: PAR).
You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.
So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!
Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...
While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...
Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.
You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.